Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.87
+0.05 (0.09%)
At close: May 1, 2026, 4:00 PM EDT
52.60
-0.27 (-0.52%)
After-hours: May 1, 2026, 7:39 PM EDT
Company Description
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 182 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 100 Marine Parkway, Suite 400 Redwood City, California 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | Chairman, President and Chief Executive Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
| James H. MacKaness | Executive Officer |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Jennifer Fulk | Chief Financial Officer |
| Jesse Schumaker | General Counsel |
| Lauren Budesheim | Senior Vice President of People |
| Kristen Yen M.S. | Senior Vice President of Global Clinical Operations and Patient Advocacy |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of New Product Planning |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Apr 29, 2026 | SC TO-T/A | Filing |
| Apr 28, 2026 | SC 14D9/A | Filing |
| Apr 28, 2026 | SC TO-T/A | Filing |
| Apr 24, 2026 | SCHEDULE 13G/A | Filing |
| Apr 20, 2026 | SC 14D9 | Filing |
| Apr 20, 2026 | SC TO-T | Filing |
| Apr 7, 2026 | 8-K | Current Report |
| Apr 7, 2026 | SC TO-C | Filing |
| Apr 6, 2026 | SC14D9C | Filing |